Related Experiment Video
Updated: May 23, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Angiogenesis inhibitors increase tumor stem cells
1Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Abstract:
The clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway has recently been met with numerous phase III failures that showed modest survival benefits. Understanding the resistance mechanisms of antiangiogenic therapy is essential to overcoming the limited effectiveness of VEGF-pathway inhibitors. A recent study published in the Proceedings of the National Academy of Sciences provides a novel explanation to the treatment limitations of angiogenesis inhibitors and suggests a potential strategy to improve the clinical utility of these agents.
Insights
Resistance to antiangiogenic therapy, targeting the vascular endothelial growth factor (VEGF) pathway, limits clinical benefits. A new study reveals novel resistance mechanisms and suggests strategies to enhance antiangiogenic drug efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) pathway has faced challenges, with many Phase III trials showing only modest survival benefits.
- Understanding the mechanisms of resistance to antiangiogenic therapy is crucial for improving patient outcomes and overcoming the limitations of current VEGF-pathway inhibitors.
Purpose of the Study:
- To provide a novel explanation for the limited clinical effectiveness of angiogenesis inhibitors.
- To suggest potential strategies for improving the clinical utility of antiangiogenic agents.
Main Methods:
- The study involved analyzing resistance mechanisms to antiangiogenic therapy.
- The research focused on agents targeting the vascular endothelial growth factor (VEGF) pathway.
Main Results:
- A novel explanation for treatment limitations of angiogenesis inhibitors was identified.
- The findings shed light on the complex resistance mechanisms developed by tumors against antiangiogenic drugs.
Conclusions:
- The study offers a new perspective on why antiangiogenic therapies, particularly those inhibiting the VEGF pathway, have shown limited success.
- Potential strategies to overcome resistance and enhance the clinical effectiveness of these agents were proposed, paving the way for improved cancer treatment.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor Immunotherapy
Mechanism of Angiogenesis
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

